| ||||
News, Publications, and Related Stories
MedPage Today -- March 23, 2010 Downregulation of the GPC5 gene may increase the risk of adenocarcinoma among never-smokers, Ping Yang, MD, Ph. View Related 
Telgraph.co.uk -- March 21, 2010 Ping Yang, from the Mayo Clinic College of Medicine, Rochester, USA, led an international team which examined DNA samples from 754 people who had never smoked. View Related 
USA Today -- Feb. 24, 2010 Matthew Goetz, M.D., hoped to settle the debate about whether CYP2D6 status affects tamoxifen users' recurrence risk. View Related 
Discovery's Edge - Mayo's Research Publication What causes brain tumors? Using statistics from Mayo’s enormous patient databases, genetics researchers are learning how genetic mutations and environmental triggers increase the risk of developing brain cancer. View Related 
Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center. 
In the May 15 issue of Cancer, Mayo researchers showed that the levels of three proteins (survivin, B7-H1, ki-67) in ccRCC tumor tissue can be used to predict which patients will ultimately die from their cancer. View Abstract 
Presented at the annual meeting of the American Association for Cancer Research (AACR). View Related
Presented at the annual meeting of the American Society of Hematology (ASH). The study focused on the impact of statin use on outcomes of patients with two most common lymphoma types, diffuse large B-cell lymphoma and follicular lymphoma. Examples of commonly used statins in the U.S. include Lipitor, Zocor, Parvachol, Lescol, Mevacor and Crestor. View Abstract 
William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic. 
Brooke Fridley, Ph.D., has joined Mayo Clinic's Comprehensive Cancer Center as a statistical geneticist to enhance pharmacogenomics studies. View Related 
The Gail model calculates probabilities that a woman will develop invasive breast cancer during the next five years, and by age 90. "We found that, for the group of women with atypia, the model predicted significantly fewer invasive breast cancers than were actually observed," says Shane Pankratz, Ph.D., Mayo Clinic statistician and a lead investigator in the study. "We also observed that the model was not able to reliably identify the women who were actually at higher risk of developing breast cancer." View Abstract 
About 7.4 percent of U.S. women have asthma. The study found that the prevalence of asthma among breast cancer patients with recurrence of their disease as metastases in the lung is two-fold higher than among non-asthmatic women with breast cancer. "If you are a breast cancer patient with asthma, taking your anti-inflammatory inhaled steroids may be more important to you than simply stopping your wheezing" says James Lee, Ph.D., a Mayo Clinic researcher in Arizona and the senior author of the study. View Abstract 
Medical Edge Newspaper I have a niece who's 15. Her mother died of inflammatory breast cancer at age 27. Her maternal grandmother died of cancer at age 37. Do you recommend gene testing? Will a positive result affect her insurance coverage? When and how should we start monitoring? View Related 
Mayo Clinic Women's HealthSource -- June 2008 Mayo Clinic Women's HealthSource is published monthly to help women enjoy healthier, more productive lives. Revenue from subscriptions is used to support medical research at Mayo Clinic. View Related
Publication: Cancer Research -- June 15, 2008 
Patient Story -- Sharon Francis Sharon Francis was working on a new design collection when the pain started. View Related 
The research team discovered that women whose atypia tissue expressed COX-2 enzymes were more likely to develop breast cancer subsequently, and that the more the enzyme expressed, the higher the risk. View Abstract
Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related
Mayo Clinic Cancer Center IDs two signatures predicting survival The team found two survival-related 50-gene signatures, one for each of the two cancer types. These were nonoverlapping and largely unique in gene content compared to previously identified predictive gene expression signatures for lung cancer developed by other researchers. View Related
Patient Story -- Janet Vittone Janet Vittone, M.D., two sisters and her mother were diagnosed with breast cancer in the same year — and received the same swift treatment at Mayo Clinic. View Related
Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related 
The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo 
Custom-fitting a Drug for a Child with Leukemia Some 20 years ago, Mayo Clinic researcher Richard Weinshilboum, M.D., and colleagues made a groundbreaking discovery: They determined why a dose of a drug that could produce astonishing cures in a lethal childhood cancer sometimes also could produce side effects that killed children. The reason behind this strikingly individual response to a drug was found in the genes. With this profound insight into the role that a patient's genetic make-up plays in how the patient responds to a drug, the new field of pharmacogenomic medicine was born. It continues to grow today—Mayo Clinic research leading the way discovering new treatment applications that range from depression, to breast cancer, to chemical dependency. View Related
Medical Edge Television There is a type of breast cancer that often doesn't show up on mammograms. It's called inflammatory breast cancer. IBC can be stopped if you know the signs and symptoms. 
The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related
Medical Edge Television One in eight. Those are the odds that your mom, sister, wife or friend has of getting breast cancer in her lifetime. The risk goes way up if you have one of two known breast cancer genes.
In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related
Renal cell carcinoma is one of most dangerous forms of kidney cancer. An interdisciplinary team of Mayo Clinic investigators and Mayo's Comprehensive Cancer Center are pursuing improved treatments by pooling data and expertise with support from Florida. "With this approach, we can halt the disease and begin to cure kidney cancer." John Copland, M.D. View Related 
Medical Edge Television Ten years ago, 48,000 women -- mothers, wives, sisters -- died every year from breast cancer. Today, that number has dropped to 40,000. But it's still too high. That's why many women who are at high risk of getting breast cancer choose genetic testing. 
Publication: Journal of Clinical Oncology -- Dec. 20, 2005 Results of a pooled analysis from the North Central Cancer Treatment Group View Related
Publication: Journal of Clinical Oncology -- May 15, 2004 North Central Cancer Treatment Group pooled results with US Gastrointestinal Intergroup and the National Surgical Adjuvant Breast and Bowel Project View Related 
|
LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE
Use of this site signifies your agreement to the terms of use.
© 2012 Mayo Foundation for Medical Education and Research. All rights reserved.
